Personalized Cancer Medicine Needs Randomized Trials
June 24, 2016
IDDI organized a webinar on Personalized Cancer Medicine Needs Randomized Trials.
Clinical cancer research is undergoing profound changes, mostly because of the advent of personalized cancer medicines. Some remarkably efficacious drugs have even been approved based on uncontrolled phase I clinical trials.
In this webinar, our speakers challenged the view that the expected benefits from new personalized cancer medicines are generally sufficient to forgo randomization to a standard-of-care arm.